Mesoblast’s aGVHD cell ther­a­py will get an­oth­er shot at the FDA

Aus­tralian biotech Mesoblast will have a sec­ond chance at an FDA ap­proval for an ex­per­i­men­tal cell ther­a­py.

In a re­lease Wednes­day, Mesoblast stat­ed the agency …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER